Last checked at 13 Dec 2022 07:00
13 December 2022
IXICO plc
("IXICO" or the "Company")
PDMR Exercise of Options
IXICO plc (AIM: IXI), the precision analytics company delivering intelligent insights in neuroscience, announces that it received notification on 12 December 2022 that Grant Nash, CFO and PDMR, exercised 200,000 share options with an exercise price of 1p. Following this transaction Grant Nash holds 200,000 shares in IXICO.
Application has been made to the London Stock Exchange for the admission to trading on AIM the 200,000 new ordinary shares of 1p each ("New Shares") to satisfy the exercise of options. The New Shares are expected to be admitted to trading on AIM on 16 December 2022.
Total voting rights
Application has been made for admission to trading on AIM of 200,000 New Shares. Following Admission of the New Shares on AIM there will be in total 48,351,373 ordinary shares in the capital of the Company in issue, each carrying equal voting rights.
This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, IXICO under the FCA's Disclosure and Transparency Rules.
Details of PDMR transaction
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Grant Nash | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| PDMR (CFO) | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| IXICO plc | |||
b)
| LEI
| 2138005M1F59O6HWSA97 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares in IXICO plc | |||
Identification code | GB00BCLY7L40 | ||||
b)
| Nature of the transaction
| Exercise of options over ordinary shares | |||
c)
| Price(s) and volume(s) | ||||
Exercise Price(s) | Volume(s) | ||||
1p | 200,000 | ||||
d)
| Aggregated information | ||||
- Aggregated volume | n/a | ||||
- Price | |||||
e)
| Date of the transaction
| 12 December 2022 | |||
f)
| Place of the transaction
| N/A | |||
For further information please contact:
IXICO plc | +44 (0)20 3763 7499 | |
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer |
| |
| ||
Cenkos Securities PLC (Nominated adviser and sole broker) | +44 (0)20 7397 8900 | |
Giles Balleny / Max Gould (Corporate Finance) | ||
Michael F Johnson / Tamar Cranford-Smith (Sales) | ||
IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.
IXICO has developed and deployed breakthrough machine learning AI data analytics, at scale, through its remote access TrialTracker technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.
More information is available on www.IXICO.com and follow us on Twitter @IXICOnews